Submission of intimation of fund raising through Preferential Issue.

Fund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹61.23

prior close

₹64.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-1.2% vs market

Healthcare Services peers, median of 51sector · industry level+0.3%-1.2% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.2 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.5

10m

-3.5

15m

-0.2

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.3-1.2+0.3-1.2

Next day

-0.2+0.8-1.0+0.6-0.9

+1.3+0.1+1.1+0.7+0.6

-2.0-0.8-1.3-0.1-1.9

-0.4-1.1+0.7-0.8+0.4

+3.0+0.2+2.8-0.3+3.3

-4.6+1.6-6.2-0.3-4.3

15d

-3.9+2.5-6.4+0.4-4.3

-8.5-2.7-5.9-2.4-6.2

+0.1-0.3+0.4-5.7+5.8

-7.5-8.9+1.5-12.7+5.2

UpDownMarket · Nifty Microcap 250Sector · Healthcare Services peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Novelix Pharmaceuticals' board has approved issuing 25,00,000 equity shares on a preferential basis to raise about Rs. 15 crore. The shares will be priced at Rs. 60 each — Rs. 10 face value plus a Rs. 50 premium — and will be allotted to 40 allottees, including promoter group member Pavani Vupparapalli (3.25 lakh shares) and 39 non-promoter investors. The move is subject to shareholder approval at an Extra Ordinary General Meeting and SEBI (ICDR) Regulations. The company has not disclosed the specific purpose of the fund raise, but the money is intended for additional capital needs.

Likely market impact

This preferential allotment will dilute existing shareholders by issuing 25 lakh new shares. Since most allottees are non-promoters and the issue is at a Rs. 50 premium over face value, it signals promoter confidence and brings in new investors, though existing shareholders will see their stake percentage reduced after EGM approval.